A study of a new drug for heart failure with obesity
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your body mass index (BMI) must be 30 or higher, which is considered obese.
- You must have been diagnosed with heart failure for at least 30 days and have some symptoms (like shortness of breath or tiredness).
- Your heart's pumping ability, called ejection fraction, must be above 40% (measured in the last year).
- You cannot have had a heart attack, heart surgery, or stroke in the last 60 days.
- You cannot have type 1 diabetes or uncontrolled type 2 diabetes with severe complications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
This study is testing whether a new class of medications, known as GLP-1/GIP receptor agonists, can help improve symptoms and heart health in people who have heart failure with preserved ejection fraction and are overweight or obese. It is a registry that tracks participants' health over time to learn about the treatment's effects.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.